Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2767 in Optic Neuropathy Due to Glaucoma
NCT07770685Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Oct 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 2 trial of ASP2767 in open-angle glaucoma (OAG), sponsored by Astellas Pharma. Started Oct 2026; status: recruiting.
02
Drugs
ASP2767
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT07770685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770685.